ClinicalTrials.gg
CompletedNCT07123987Updated Oct 29, 2026Results posted

Transcutaneous Auricular Vagus Nerve Stimulation on Post-Herpetic Neuralgia

An interventional study of transcutaneous auricular vagus nerve stimulation (taVNS) and traditional medical treatment for PHN in Post Herpetic Neuralgia (PHN), sponsored by Mohamed Hosny Ismail Easa. Completed at 1 site in Egypt. Open to participants aged 35 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Mohamed Hosny Ismail Easa · Not applicable, Interventional, and Treatment

How we know

Updated Oct 29, 2026Now CompletedResults posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
35 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Neuralgia, Postherpetic with a site in Egypt — 4 open to participants now, 4 under way, none of them phase 3. Neuralgia, Postherpetic · Egypt.

Enrollment
10th of 10
34 · median 56
Started
2025
with 4 others
No phase
9 of 10
4 open now
Registered
6th of 10
by date
Lead sponsor
1 of 10
Mohamed Hosny Ismail Easa

Among the 10 studies in Neuralgia, Postherpetic with a site in Egypt, this one is the 10th largest by enrollment, is one of 5 that started in 2025, is one of 9 with no phase, and was the 6th registered.

Neuralgia, Postherpetic

197 studies on the registry are indexed under Neuralgia, Postherpetic; 29 are open to participants now.

Browse Neuralgia, Postherpetic studies →

Open to participants now

4 of the 10 studies in Neuralgia, Postherpetic with a site in Egypt are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 18 Neuralgia, Postherpetic studies recruiting now, 8 (44%) set no upper age limit and 5 (28%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 35 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Neuralgia, Postherpetic with a site in Egypt, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the therapeutic efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) in the treatment of patients with post-herpetic neuralgia (PHN). Participants will receive taVNS in addition to standard care. The study aims to determine whether taVNS can provide significant pain relief and improve quality of life in PHN patients.

Read the detailed description

Post-herpetic neuralgia (PHN) is a chronic neuropathic pain condition that persists for months or years following the resolution of herpes zoster (HZ) infection. It is characterized by persistent burning, stabbing, or shooting pain, often accompanied by allodynia and hyperalgesia, which can significantly impair quality of life. Current treatment options for PHN, including pharmacological therapies, often provide incomplete pain relief and are associated with side effects, creating a need for novel, non-invasive interventions.

This randomized controlled trial aims to evaluate the therapeutic efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) as an adjunct to standard medical treatment for patients with PHN. The vagus nerve plays a crucial role in modulating pain perception and inflammatory processes, and its non-invasive stimulation through the auricular branch has shown promising analgesic effects in various chronic pain syndromes.

A total of 34 male and female participants, aged 35-65 years, diagnosed with PHN will be randomly allocated into two equal groups (17 participants per group). Group A (Experimental) will receive taVNS in addition to conventional pharmacological management, while Group B (Control) will receive conventional pharmacological management alone. The taVNS intervention will be delivered using the EV-906 device with TENS ear clips, applied according to the study protocol and safety standards (ISO 13485, FDA QSR, and CE compliance).

Pain intensity and quality will be assessed at baseline, after two weeks, and after four weeks using validated outcome measures: the Brief Pain Inventory (BPI) short form and the Short-form McGill Pain Questionnaire-2 (SF-MPQ-2). The primary outcome is the change in pain severity scores, and the secondary outcome is the change in pain interference with daily activities.

The results of this study will provide evidence regarding the clinical utility of taVNS as a safe, non-invasive, and effective adjunct therapy for PHN, with the potential to improve patient outcomes and quality of life

03

Conditions studied

  • Post Herpetic Neuralgia (PHN)

Keywords

  • Post-Herpetic Neuralgia
  • Neuropathic Pain
  • Herpes Zoster
  • Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
  • Non-invasive Neuromodulation
  • Chronic Pain Management
  • Pain Relief
  • Randomized Controlled Trial
04

Who can participate

Ages eligible
35 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adults aged 35-65 years diagnosed with PHN. Persistent pain for at least 3 months after herpes zoster infection. Only patients who sign the form will be included.

Exclusion criteria

Exclusion Criteria:

to taVNS such as:

  1. pregnancy;
  2. active implants (e.g., pacemakers, cochlear implants) or brain shunts;
  3. previous neurological or psychiatric diagnoses;
  4. history of addiction or substance abuse;
  5. history of trauma and/or brain surgery;
  6. cardiac disease;
  7. acute or chronic use of medications and/or illicit drugs;
  8. susceptibility to headaches and seizures. Severe cognitive impairment. Other chronic pain conditions.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Group (A): Study group

    this group will receive taVNS in addition to traditional medical treatment

    Device: transcutaneous auricular vagus nerve stimulation (taVNS)

  • Active comparator
    Group (B): Control group

    this group will receive the same traditional medical treatment only

    Other: traditional medical treatment for PHN

Interventions

  • Devicetranscutaneous auricular vagus nerve stimulation (taVNS)

    Use of the EV-906 device with TENS ear clips for transcutaneous auricular vagus nerve stimulation (taVNS), applied according to the study protocol, in addition to standard medical treatment for post-herpetic neuralgia. This device meets ISO 13485, FDA QSR, and CE standards

  • Othertraditional medical treatment for PHN

    Standard medical treatment for post-herpetic neuralgia as per current clinical guidelines, without the application of taVNS device.

06

What researchers measure

Primary outcomes

  1. Brief Pain Inventory-Short Form (BPI-SF) Total Score

    the Brief Pain Inventory-Short Form (BPI SF) is a valuable tool for assessing pain severity and its impact on daily functioning on a 0-10 numeric rating scale, with higher scores indicating more severe pain.

    Time frame: Baseline, 2 weeks, and 4 weeks

  2. Short Form McGill Pain Questionnaire 2 (SF-MPQ-2)

    The SF-MPQ-2 is a validated tool assessing sensory, affective, and evaluative qualities of pain. Participants rate the intensity of their pain using a 0-10 scale: 0: No pain 10: Worst pain imaginable Participants select the rating that best reflects their experience during the past week.

    Time frame: Administered three times: before the first treatment session, after 2 weeks, and after 4 weeks. Administration mode: Interview-based.

07

Results

Posted Oct 29, 2026
Limitations and caveats
Despite the promising findings, several limitations of the present study should be acknowledged. First, the relatively small sample size, although statistically justified, may limit the generalizability of the results to the broader PHN population. Larger multicenter trials are needed to confirm these findings across diverse demographic and clinical settings. Second, the duration of follow-up was limited to the four-week intervention period, and long-term outcomes beyond the treatment phase wer

Participant flow

Thirty-four (34) patients diagnosed with post-herpetic neuralgia (PHN) were recruited for this study. Participants were aged between 35 and 65 years and included both sexes. They were recruited from the Pain Clinic of Zagazig University Hospitals. Eligible participants were randomly assigned into two equal groups (n = 17 per group).

Participant flow — Overall Study
MilestoneGroup (A): Study GroupGroup (B): Control Group
Started1717
Completed1717
Not completed00

Outcome measures

PrimaryBrief Pain Inventory-Short Form (BPI-SF) Total Score

the Brief Pain Inventory-Short Form (BPI SF) is a valuable tool for assessing pain severity and its impact on daily functioning on a 0-10 numeric rating scale, with higher scores indicating more severe pain.

Time frame:
Baseline, 2 weeks, and 4 weeks
Reported as:
Mean · points
Brief Pain Inventory-Short Form (BPI-SF) Total Score
pointsGroup (A): Study GroupGroup (B): Control Group
baseline scores6.73 ± 1.116.29 ± 1.22
after 2 weeks scores4.52 ± 1.124.88 ± 1.30
after 4 weeks scores2.95 ± 1.163.92 ± 1.69
Statistical analysis
  • Group (A): Study Group vs Group (B): Control Group · t-test, 2 sided · p = 0.040 · Mean difference (net): -0.80 · 95% CI -1.25 to -0.35
PrimaryShort Form McGill Pain Questionnaire 2 (SF-MPQ-2)

The SF-MPQ-2 is a validated tool assessing sensory, affective, and evaluative qualities of pain. Participants rate the intensity of their pain using a 0-10 scale: 0: No pain 10: Worst pain imaginable Participants select the rating that best reflects their experience during the past week.

Time frame:
Administered three times: before the first treatment session, after 2 weeks, and after 4 weeks. Administration mode: Interview-based.
Reported as:
Mean · score
Short Form McGill Pain Questionnaire 2 (SF-MPQ-2)
scoreGroup (A): Study GroupGroup (B): Control Group
baseline scores6.73 ± 1.116.29 ± 1.22
after 2 weeks scores4.52 ± 1.124.88 ± 1.30
after 4 weeks scores2.95 ± 1.163.92 ± 1.69
Statistical analysis
  • Group (A): Study Group vs Group (B): Control Group · t-test, 2 sided · p = 0.040 (Two-sided statistical test comparing the study and control groups.) · Mean difference (net): -0.80 · 95% CI -1.25 to -0.35P-value was calculated using the specified statistical test.

Adverse events

Collected over From enrollment until 4 weeks after treatment.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group (A): Study Group0/17 (0%)0/17 (0%)0/17 (0%)
Group (B): Control Group0/17 (0%)0/17 (0%)0/17 (0%)

Baseline characteristics

All randomized participants were included in the baseline analysis

Age, Customized
Age, Customized(years)Group (A): Study GroupGroup (B): Control GroupTotal
age Baseline Characteristics53.5 ± 6.755.4 ± 5.354.45 ± 6.03
Sex: Female, Male
Sex: Female, Male(Participants)Group (A): Study GroupGroup (B): Control GroupTotal
Female5914
Male12820
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Group (A): Study GroupGroup (B): Control GroupTotal
Count of participants——0
Brief Pain Inventory short form total score at baseline
Brief Pain Inventory short form total score at baseline(points)Group (A): Study GroupGroup (B): Control GroupTotal
Mean6.73 ± 1.116.29 ± 1.226.51 ± 1.16
08

Study locations

1 site
  • Faculty of Physical Therapy - Cairo University
    Cairo, Giza Governorate 12613, Egypt
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Data will not be shared due to participant confidentiality and restrictions imposed by the institutional ethics committee

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2025 to primary completion in Sep 2026, 12 months.

Results were first posted in Oct 2026, 1 month after primary completion.

Of 30 non-industry interventional studies with no phase under Neuralgia, Postherpetic, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 35. This study's 12 months is below that.

Counting every sponsor, half of 32 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2025
First posted
Aug 15, 2025
StartActual
Sep 7, 2025
Primary completionActual
Sep 9, 2026
CompletionActual
Sep 9, 2026
Results first posted
Oct 29, 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 29, 2026
Results
Results posted
posted Oct 29, 2026
Primary outcomes
1 edited, 1 added
What changed in the outcomes
  • EditedBrief Pain Inventory - Short Form (BPI-SF) Total ScoreTime frame: Administered three times: before the first treatment session, after 2 weeks, and after 4 weeks. Administration mode: Interview-based. → Baseline, 2 weeks, and 4 weeks
  • AddedShort Form McGill Pain Questionnaire 2 (SF-MPQ-2)Time frame: Administered three times: before the first treatment session, after 2 weeks, and after 4 weeks. Administration mode: Interview-based.
Oct 29, 2026
Documents
Secondary outcomes
1 removed
What changed in the outcomes
  • RemovedShort form McGill pain questionnaire 2 (SF-MPQ-2)Time frame: Administered three times: before the first treatment session, after 2 weeks, and after 4 weeks. Administration mode: Interview-based.
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Recruiting→Completed
    Results posted
    Primary outcomes 1 edited, 1 added
    What changed in the outcomes
    • EditedBrief Pain Inventory - Short Form (BPI-SF) Total ScoreTime frame: Administered three times: before the first treatment session, after 2 weeks, and after 4 weeks. Administration mode: Interview-based. → Baseline, 2 weeks, and 4 weeks
    • AddedShort Form McGill Pain Questionnaire 2 (SF-MPQ-2)Time frame: Administered three times: before the first treatment session, after 2 weeks, and after 4 weeks. Administration mode: Interview-based.
    Secondary outcomes 1 removed
    What changed in the outcomes
    • RemovedShort form McGill pain questionnaire 2 (SF-MPQ-2)Time frame: Administered three times: before the first treatment session, after 2 weeks, and after 4 weeks. Administration mode: Interview-based.
    + 4 other changes: verification date, date precision, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07123987
Lead sponsor
Mohamed Hosny Ismail Easa
Responsible party
Mohamed Hosny Ismail Easa (Principal Investigator, MSc Candidate, Faculty of Physical Therapy, Cairo University, Cairo University) — Sponsor-investigator
First posted
Aug 15, 2025
Start date
Sep 7, 2025
Primary completion
Sep 9, 2026
Completion
Sep 9, 2026
Results posted
Oct 29, 2026
Last update
Oct 29, 2026

Study contacts

Wafaa Hussein Borhan, PhD
study chair · Professor of Physical Therapy for Surgery Department, Faculty of Physical Therapy, Cairo University
Rofaida El Sayed El Naggar, MD
study director · Lecturer of Dermatology, Kasr Alainy, Faculty of Medicine, Cairo University
Doaa Atef Aly, PhD
study director · Lecturer of Physical Therapy for Surgery Department, Faculty of Physical Therapy, Cairo University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion